MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
37.39
+1.27
+3.52%
Opening 13:02 05/29 EDT
OPEN
36.64
PREV CLOSE
36.12
HIGH
37.74
LOW
36.27
VOLUME
117.99K
TURNOVER
--
52 WEEK HIGH
47.84
52 WEEK LOW
3.260
MARKET CAP
2.34B
P/E (TTM)
-8.9578
1D
5D
1M
3M
1Y
5Y
1D
Kodiak Sciences CEO to present at Jefferies Global Healthcare Conference
PUBT · 19h ago
Weekly Report: what happened at KOD last week (0518-0522)?
Weekly Report · 4d ago
Weekly Report: what happened at KOD last week (0511-0515)?
Weekly Report · 05/18 10:12
J.P. Morgan Remains a Buy on Kodiak Sciences (KOD)
TipRanks · 05/14 12:09
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 05/12 15:01
Kodiak Sciences upgraded to Buy from Neutral at Chardan
TipRanks · 05/11 16:59
This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Benzinga · 05/11 13:24
Kodiak Sciences Raised to Buy From Neutral by Chardan Capital
Dow Jones · 05/11 12:21
More
About KOD
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.